Replimune Group Inc.

Last updated September 27, 2026

Favorite this organization

Organization details

Legal name: Replimune Group Inc.
Ownership: Public
Status: Active
Sector (GICS): Health Care
SIC code: 2836 — Biological Products, (No Diagnostic Substances)
Jurisdiction of incorporation: Delaware
Headquarters city: Woburn
Headquarters state / province: Massachusetts
Headquarters country: United States
Fiscal year end: March
Ticker symbol: REPL
Primary stock exchange: Nasdaq

Identifiers

SEC CIK: 0001737953
EIN: 82-2082553

Board of directors

Follow this board

Christy J. Oliger · Director Overboarded
Since 2023
Dieter Weinand · Director
Since 2023
Felix Baker · Director Overboarded
Since 2025
Hugo Alexander Slootweg · Director
Since 2023
Hyam Levitsky · Director
Since 2023
Joseph P. Slattery · Director
Since 2023
Julian Baker · Director Overboarded
Since 2025
Kapil Dhingra · Director
Since 2023
Madhavan Balachandran · Director
Since 2024
Michael Goller · Director
Since 2025
Paolo Pucci · Director
Since 2023
Philip Astley-Sparke · Director · Executive Chairman
Since 2023
Robert Coffin · Director · President & Chief R&D Officer
Since 2023
Sushil Patel · Director · Chief Executive Officer
Since 2024
Veleka Peeples-Dyer · Director
Since 2023

Chief executives

Philip Astley-Sparke · Chief Executive Officer

Dates unknown

Sushil Patel · Chief Executive Officer

Dates unknown

Director election results

Annual meeting of September 2, 2025. Support is votes for as a share of votes for and against (or withheld). Below 80% is a clear protest.

Board connections

11 of this board's directors also sit on 29 other boards. 29 are in the same sector.

Shared director Other board Same sector +13 more in the list below

ACADIA Pharmaceuticals Inc. Same sector
via Felix Baker and Julian Baker
BeOne Medicines Ltd. Same sector
via Felix Baker and Julian Baker
Bicycle Therapeutics plc Same sector
via Felix Baker and Julian Baker
DBV Technologies S.A. Same sector
via Felix Baker and Julian Baker
Denali Therapeutics Inc. Same sector
via Felix Baker and Julian Baker
Immunocore Holdings plc Same sector
via Felix Baker and Julian Baker
Incyte Corp. Same sector
via Felix Baker and Julian Baker
Kiniksa Pharmaceuticals International plc Same sector
via Felix Baker and Julian Baker
Kodiak Sciences Inc Same sector
via Felix Baker and Julian Baker
Kymera Therapeutics Inc. Same sector
via Felix Baker and Julian Baker
Madrigal Pharmaceuticals Inc. Same sector
via Felix Baker and Julian Baker
Neurogene Inc. Same sector
via Felix Baker and Julian Baker
Prelude Therapeutics Incorporated Same sector
via Felix Baker and Julian Baker
TScan Therapeutics Inc. Same sector
via Felix Baker and Julian Baker
vTv Therapeutics Inc. Same sector
via Felix Baker and Julian Baker
Bicara Therapeutics Inc. Same sector
via Christy J. Oliger
Black Diamond Therapeutics Inc. Same sector
via Kapil Dhingra
CVRx Inc. Same sector
via Joseph P. Slattery
Coya Therapeutics Inc. Same sector
via Dieter Weinand
ImageneBio Inc. Same sector
via Joseph P. Slattery
Karyopharm Therapeutics Inc. Same sector
via Christy J. Oliger
NewAmsterdam Pharma Company N.V. Same sector
via Hugo Alexander Slootweg
Revolution Medicines Inc. Same sector
via Sushil Patel
Stevanato Group S.p.A. Same sector
via Madhavan Balachandran
Vera Therapeutics Inc. Same sector
via Christy J. Oliger
West Pharmaceutical Services Inc. Same sector
via Paolo Pucci
Zenas BioPharma Inc. Same sector
via Christy J. Oliger
enGene Therapeutics Inc. Same sector
via Philip Astley-Sparke
uniQure N.V. Same sector
via Madhavan Balachandran

Insider trades

All notable trades →

From SEC Forms 4 and 5. Open-market purchases and sales are highlighted; grants, option exercises and shares withheld for tax are routine.

Bought, last 12 months: $0; 0 purchases by 0 insiders
Sold, last 12 months: $2,454,923; 19 sales by 8 insiders

Date	Insider	Transaction	Shares	Price	Value
Nov 9, 2026	Joseph P. Slattery Director	Open-market sale	−5,200	$21.80	$113,360
Nov 2, 2026	Kapil Dhingra Director	Option exercise	+43,169	$1.75	$75,546
Nov 2, 2026	Kapil Dhingra Director	Open-market sale	−21,500	$19.00	$408,500
Aug 20, 2026	Philip Astley-Sparke Director	Gift	−50,000	—	—
Aug 17, 2026	Hill Emily Luisa Officer (Chief Financial Officer)	Open-market sale	−9,256	$14.28	$132,176
Aug 10, 2026	Hill Emily Luisa Officer (Chief Financial Officer)	Open-market sale	−11,448	$12.97	$148,481
Aug 10, 2026	Sushil Patel Director, Officer (Chief Executive Officer)	Open-market sale	−39,341	$12.97	$510,253
Aug 10, 2026	Schwendenman Andrew Officer (Chief Accounting Officer)	Open-market sale	−7,632	$12.97	$98,987
Aug 10, 2026	Xynos Konstantinos Officer (Chief Medical Officer)	Open-market sale	−11,447	$12.97	$148,468
Jun 1, 2026	Sarchi Christopher Officer (Chief Commercial Officer)	Open-market sale	−12,000	$9.24	$110,880
May 18, 2026	Xynos Konstantinos Officer (Chief Medical Officer)	Open-market sale	−14,023	$5.08	$71,237
May 18, 2026	Schwendenman Andrew Officer (Chief Accounting Officer)	Open-market sale	−7,894	$5.08	$40,102
May 18, 2026	Sarchi Christopher Officer (Chief Commercial Officer)	Open-market sale	−8,626	$5.08	$43,820
May 18, 2026	Philip Astley-Sparke Director	Open-market sale	−17,657	$5.08	$89,698
May 18, 2026	Sushil Patel Director, Officer (Chief Executive Officer)	Open-market sale	−37,324	$5.08	$189,606

Peers

Compare boards

Organizations in the same sector, closest in location and size first.

3M Company NYSE: MMM · ST Paul, United States Organization ABVC BioPharma Inc. Nasdaq: ABVC · Fremont, United States Organization ACADIA Pharmaceuticals Inc. Nasdaq: ACAD · SAN Diego, United States Organization ADMA Biologics Inc Nasdaq: ADMA · Ramsey, United States Organization

Questions about Replimune Group Inc.

Who is the CEO of Replimune Group Inc.?

Philip Astley-Sparke is Replimune Group Inc.'s Chief Executive Officer.

How many directors are on Replimune Group Inc.'s board?

Replimune Group Inc.'s board has 15 directors: Christy J. Oliger, Dieter Weinand, Felix Baker, Hugo Alexander Slootweg, Hyam Levitsky, Joseph P. Slattery, Julian Baker, Kapil Dhingra, Madhavan Balachandran, Michael Goller and 5 others.

Are Replimune Group Inc. insiders buying or selling shares?

Over the last 12 months, Replimune Group Inc. insiders made no open-market purchases and sold $2.5 million of shares in 19 sales on the open market, as reported to the SEC on Forms 4 and 5.

How is Replimune Group Inc. connected to…? → Spot something wrong? Report a correction

Embed this board on your site

Paste this where the board should appear. It always shows the current directors and links back here.

<div data-bod-board="replimune-group-inc"></div>
<script src="https://boardofdirectors.review/embed.js" async></script>

Reviews (0)

No reviews yet. Be the first to write one.